# 12/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center

> **NIH NIH U01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $370,129

## Abstract

PROJECT SUMMARY
12/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
We submit this application in response to RFA-DK-22-506. UCSF is a current member of the APOLLO
Consortium. This Consortium was established in 2017 to work seamlessly with the Association of Organ
Procurement Organizations (AOPO) to enroll participants in the largest observational study to date of kidney
transplant recipients and donors to evaluate APOL1 gene mutations as a risk factor for graft loss. Our Clinical
Center has been a leader on the West Coast, collaborating with our sites at University of California Los
Angeles, University of California Davis (UC Davis), California Pacific Medical Center (CPMC), Stanford
University, and University of Southern California. In Phase 1 or APOLLO, we have successfully enrolled a total
of 223 participants across these centers, with DNA specimens in hand for 221/223. Our site has overseen the
careful collection of clinical data from the electronic medical record at our own site and those of our engaged
centers to complete the APOLLO Consortium Data forms accurately and completely. In Phase 2, we will
continue to obtain critical follow-up data on all participants and ensure completion of data abstraction from
electronic medical record continues at our engaged sites, to provide patient-level detail not available in
databases maintained by United Network for Organ Sharing (UNOS) and the Scientific Registry of Transplant
Recipients (SRTR). We will ensure a urine albumin-to-creatinine ratio is measured in all participants, at all
sites, at a longitudinal follow-up time point at least two years after transplantation in APOLLO Phase 1. We will
collect additional biospecimens for contribution to the biorespository as well as unstained biopsy slides as we
have been doing through Phase 1. We will work with the Scientific Data and Coordinating Center to ensure
return of genotype results to all study participants who desire this information. We will also continue to recruit
living donors at our site. Continuation of the APOLLO Consortium will lead to important advances in our
understanding of APOL1 high-risk status and its influence on graft function as well as the biology of APOL1
gene effects.

## Key facts

- **NIH application ID:** 10730991
- **Project number:** 2U01DK116043-06
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Chi-yuan Hsu
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $370,129
- **Award type:** 2
- **Project period:** 2017-09-25 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10730991

## Citation

> US National Institutes of Health, RePORTER application 10730991, 12/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center (2U01DK116043-06). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10730991. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*